Hard Brexit: MHRA Preparations
Recommendation
10/11 February 2026
Heidelberg, Germany
Medicinal Products/Drugs meet Medical Devices
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
Boris Johnson's election as Prime Minister has made it very likely that the UK will leave the EU on 31 October this year. And the likelihood of a withdrawal without an agreement ("Hard Brexit ") can no longer be dismissed. Pharmaceutical authorities see challenges for pharmaceutical manufacturers in many areas, not only in terms of drug availability or drug testing.
The MHRA has already published several guidelines for a possible no-deal scenario. This concerns the following areas:
- Medical Devices
- Clinical Trials
- Biologicals and ATMPs
- List if approved countries
- Trading in drug precursors
- QPPV and PV Master File
A comprehensive overview can be found in the Collection "MHRA guidance and publications about a possible no-deal Brexit".
Related GMP News
21.01.2026EU Pharma Package: EMA with single Point of Information
20.01.2026New Ph. Eur. Publication Schedule
14.01.2026European QP Association Developments September through December 2025
14.01.2026Could a change of ownership be relevant to GMP?
07.01.2026Is QP Certification required when Products do not enter EU Territory?
17.12.2025EU Reaches Landmark on Reform of Pharmaceutical Legislation